Skip to content

Obesity: Prospective Evaluation of Upper Airway Obstruction and Compliance in Obese Patients in Pre and Post Bariatric Surgery

Obesity: Prospective Evaluation of Upper Airway Obstruction and Compliance in Obese Patients in Pre and Post Bariatric Surgery : A Monocentric Observational Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03360565
Acronym
OBANEZ
Enrollment
130
Registered
2017-12-04
Start date
2016-03-02
Completion date
2020-03-02
Last updated
2017-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bariatric Surgery, Obesity

Keywords

Obstructive Sleep Apnea Syndrome (OSAS)

Brief summary

This clinical trial is a monocentric, prospective, observational and controlled trial (historical cohort control group of healthy non-obese subjects who had Nasal functional exploration for Snoring) as part of current care. This study concerns the prevalence of obstructive sleep apnea syndrome (OSAS). OSAS is elevated in subjects with morbid obesity (BMI≥40) (on average 70%). International recommendations agree on the need to seek OSAS before bariatric surgery because of the high risk of complications. Increased nasal resistance could also be related to a limitation of inspiratory flow due to an abnormality of the elasticity of the nasal mucosa or nasal compliance. Adipose infiltration of the nasal mucosa may occur during obesity. These tissue changes (decreased vaso-erectile tissue and increased adipose tissue) could modify the nasal compliance, which the decrease would be a possible factor of severity of OSAS in obese patients. Screening for an abnormality of compliance could also anticipate a difficulty of equipment for Continuous Positive Airway Pressure (CPAP) in the case of associated OSAS. All patients who must have bariatric surgery and get in the criteria are included. They will have to do a medical checkup pre and post-operative (polygraphy + ear/nose/throat assessment (ENT) + Nasal functional exploration). They will be followed for 13 to 24 months. The main objective of this research is to demonstrate a reduction of at least 30% of nasal compliance in a group of obese subjects (BMI\> 35) compared to a control group of healthy subjects. The secondary objectives are to is to demonstrate an increase of 30% in resistance in patients with BMI\> 35 compared to control group and a normalization of nasal compliance 1 year after surgery when their weight is normalized (BMI \<30). A study period of 4 years is planned.

Interventions

None listed

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Voluntary Patient * Patients aged 18 years or older. * BMI \> 35 * Patient included in the bariatric surgery protocol * Medical checkup :polygraphy and Respiratory Functional Exploration (RFE)

Exclusion criteria

* Impossible to obtain a consent or age less than 18 years * Heart / Kidney Failure * Absence of affiliation to a Social Security scheme * History of rhinological surgery * Pregnancy, Breastfeeding * Subject presenting a congenital or acquired obstructive nasal obstructive physical obstacle (obstructive deviation, craniofacial malformation)

Design outcomes

Primary

MeasureTime frame
To demonstrate a reduction of at least 30% of nasal compliance in a group of obese subjects (BMI> 35) compared to a control group of healthy subjectsbefore bariatric surgery

Secondary

MeasureTime frame
To demonstrate an increase of 30% in resistance in patients with BMI> 35 compared to control groupbefore bariatric surgery
To demonstrate a normalization of nasal compliance when the weight is normalized (BMI <30)9 month (+3month) after bariatric surgery

Countries

France

Contacts

Primary ContactEmilie BEQUIGNON, PH
emilie.bequignon@gmail.com(0)1 49 81 24 91

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026